Ardelyx’s (ARDX) Outperform Rating Reiterated at Wedbush

Wedbush reaffirmed their outperform rating on shares of Ardelyx (NASDAQ:ARDX) in a research note published on Monday,Benzinga reports. They currently have a $19.00 price target on the biopharmaceutical company’s stock.

ARDX has been the topic of several other reports. HC Wainwright raised their target price on Ardelyx from $10.00 to $18.00 and gave the company a “buy” rating in a report on Friday, February 20th. TD Cowen reaffirmed a “buy” rating on shares of Ardelyx in a research report on Thursday, January 29th. Piper Sandler upgraded shares of Ardelyx from a “neutral” rating to an “overweight” rating and upped their target price for the company from $10.00 to $16.00 in a research note on Thursday, January 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ardelyx in a report on Wednesday, January 21st. Finally, BTIG Research reiterated a “buy” rating and issued a $17.00 price objective on shares of Ardelyx in a report on Friday, February 20th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $15.09.

Ardelyx Stock Performance

Shares of ARDX stock opened at $6.56 on Monday. The company has a current ratio of 4.31, a quick ratio of 4.11 and a debt-to-equity ratio of 1.21. The company has a market cap of $1.61 billion, a PE ratio of -26.24 and a beta of 0.57. The company’s fifty day simple moving average is $6.79 and its 200-day simple moving average is $6.14. Ardelyx has a 52 week low of $3.21 and a 52 week high of $8.40.

Ardelyx (NASDAQ:ARDX) last announced its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.03). Ardelyx had a negative net margin of 15.12% and a negative return on equity of 40.63%. The company had revenue of $125.22 million during the quarter, compared to analyst estimates of $118.04 million. During the same quarter in the prior year, the company posted $0.02 earnings per share. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. As a group, equities research analysts anticipate that Ardelyx will post -0.18 EPS for the current year.

Insider Transactions at Ardelyx

In other news, insider Joseph James Reilly sold 4,991 shares of the business’s stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $5.85, for a total value of $29,197.35. Following the completion of the sale, the insider owned 151,790 shares of the company’s stock, valued at approximately $887,971.50. The trade was a 3.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mike Kelliher sold 9,595 shares of the company’s stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $5.85, for a total transaction of $56,130.75. Following the completion of the sale, the insider owned 364,666 shares in the company, valued at approximately $2,133,296.10. This trade represents a 2.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 136,938 shares of company stock valued at $857,587 over the last ninety days. 4.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Ardelyx

Several institutional investors and hedge funds have recently bought and sold shares of the company. First Horizon Corp grew its position in shares of Ardelyx by 120.4% in the 4th quarter. First Horizon Corp now owns 7,906 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 4,319 shares in the last quarter. DCF Advisers LLC bought a new position in Ardelyx during the second quarter worth $39,000. Brighton Jones LLC acquired a new position in Ardelyx in the second quarter worth $40,000. SBI Securities Co. Ltd. increased its stake in Ardelyx by 147.0% during the third quarter. SBI Securities Co. Ltd. now owns 10,253 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 6,102 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. bought a new stake in Ardelyx during the fourth quarter valued at $60,000. Institutional investors and hedge funds own 58.92% of the company’s stock.

Trending Headlines about Ardelyx

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Director David M. Mott purchased 333,333 shares (~$1.95M) at about $5.84, increasing his stake by ~11.2% — a strong insider vote of confidence that can support the share price. Read More.
• Positive Sentiment: Ardelyx announced a multi‑year marketing partnership with the LPGA to raise awareness around digestive health — a branding/awareness initiative that could help commercial uptake of XPHOZAH. Read More.
• Positive Sentiment: Several brokers reiterated or raised bullish ratings/targets (Wedbush outperform with a ~$19 target, BTIG, HC Wainwright, Citi upgrades), which can attract buyers and lift sentiment. Read More.
• Neutral Sentiment: Quarterly revenue beat ($125.2M vs. $118.0M) and ~7.8% YoY revenue growth — constructive for fundamentals but partially offset by profitability misses. Read More.
• Neutral Sentiment: Short interest data published shows effectively no reported short interest (odd/possibly stale data) — not currently a driver of short‑squeeze dynamics.
• Negative Sentiment: EPS missed expectations (reported a $0.01 loss vs. ~$0.02 expected), which prompted a post‑earnings sell‑off and raised near‑term sentiment risk. Read More.
• Negative Sentiment: Multiple insiders (including CEO Michael Raab, CFO Susan Hohenleitner and others) sold shares on Feb 20 (CEO sold ~45,982 shares), which investors may read as profit‑taking and can pressure sentiment. Read More.

Ardelyx Company Profile

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.